Mineralys Therapeutics presented its clinical trial results at the American Heart Association sessions in Baltimore.
4 reports, 2 independent
Updated Sep 1
Mostly repetition
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Mineralys Therapeutics presented its clinical trial results at the American Heart Association sessions in Baltimore.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Also in this story
- Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
- Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
- Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.
The entities involved
-
American Heart Association
US nonprofit funding cardiovascular medical research, educating consumers on healthy living, and fostering cardiac care
Coverage
Newest first; wire copies grouped- GlobeNewswireMineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need ~Pivotal Laun
- Insider MonkeyMineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak We recently published 10 Power Stocks Crushing Wall Street — 7 at All-Time Highs. Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is